AUSTRALIA'S #1 ONLINE CPD EDUCATION PLATFORM

Advertisement

Lilly unites caring with discovery to create medicines that make life better for people around the world. Over 140 years and nearly 100 medicines later, we continue to seek the next great discovery and to uncover even more ways to make life better for people around the world.

 

T2D injectables: 1. Intensifying to first injectable therapy in uncomplicated type 2 diabetes

This education module focuses on a case study of an uncomplicated patient with type 2 diabetes, and the process of intensifying to first injectable therapy. Expert video commentary throughout the module helps step the participant through the decision cycle from the ADA/EASD consensus guidelines for T2D. This module also includes Australian recommendations for patients fasting during Ramadan.

T2D injectables: 2. Intensifying to first injectable therapy in patients with ASCVD risk

In this education module, the participant will work through a case study of a type 2 diabetes patient with ASCVD risk factors. The case study uses the decision cycle from the ADA/EASD consensus guidelines for T2D, and features expert video commentary. The module also discusses patient-related concerns leading to clinical inertia, including useful management decisions when faced with this issue.

T2D injectables: 3. Intensifying to first injectable therapy in patients with established ASCVD

This education module takes a case-study based look at the management of a type 2 diabetes patient with established ASCVD. Featuring expert video commentary, participants will use the decision cycle from the ADA/EASD consensus guidelines for T2D to work through a hypothetical case study. This module also discusses GP-related causes of clinical inertia, as well as additional patient factors such as obesity, low health literacy and diabetes distress.

Rethinking first injectable therapies in type 2 diabetes: A practical approach

This accredited learning module explores how to initiate injectable therapy in a patient with type 2 diabetes who remains above their glycaemic target despite taking dual or triple oral therapy. The activity works through 3 in-depth case-studies: a patient with uncomplicated T2D, a patient with ASCVD risk, and a patient with established ASCVD.